CVRx Faces Volatility as Barostim® Pushes Heart Failure Innovation
CVRx’s Barostim® neuromodulation device promises breakthrough heart‑failure treatment, yet its stock’s steep decline highlights financial risk and investor scrutiny ahead of Q3 2026 results.
3 minutes to read